NEWS AND PUBLICATIONS

FundaMental Pharma GmbH (‘FundaMental’ or ‘The Company’), a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, is pleased to announce the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member.

FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director. Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative diseases based on a breakthrough molecular mechanism

FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis.

FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant.

High-Tech Gründerfonds (HTGF) provides seed funding for the neuro start-up FundaMental Pharma GmbH (FMP), a spin-off of the Interdisciplinary Center for Neuroscience (IZN) at Heidelberg University.

Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents

Heidelberg researchers investigate new approaches to treating neurodegenerative diseases